{"nctId":"NCT00833248","briefTitle":"Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer","startDateStruct":{"date":"2009-04"},"conditions":["Prostate Cancer"],"count":246,"armGroups":[{"label":"Degarelix 240 mg/80 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Degarelix"]},{"label":"Goserelin (3.6 mg) + bicalutamide (50 mg)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Goserelin","Drug: Bicalutamide"]}],"interventions":[{"name":"Degarelix","otherNames":["FE200486","Firmagon"]},{"name":"Goserelin","otherNames":["Zoladex"]},{"name":"Bicalutamide","otherNames":["Casodex"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient has given written informed consent before any trial-related activity is performed.\n* Has a confirmed prostate cancer in which this type of treatment is needed.\n\nExclusion Criteria:\n\n* Previous treatment for prostate cancer\n* Previous trans-urethral resection of the prostate\n* Patients who are lymph node positive or have other metastatic disease\n* Use of urethral catheter\n* Current treatment with a 5-alpha reductase inhibitor or Î±-adrenoceptor antagonist.\n* History of severe untreated asthma, anaphylactic reactions, or severe urticaria and/or angioedema.\n* Hypersensitivity towards any component of the investigational product\n* Other previous cancers within the last five years with the exception of prostate cancer and some types of skin cancer.\n* Certain risk factors for abnormal heart rhythms/QT prolongation (corrected QT interval over 450 msec., Torsades de Pointes or use of certain medications with potential risk)\n* Clinical disorders other than prostate cancer including but not limited to renal, haematological, gastrointestinal, endocrine, cardiac, neurological, psychiatric disease, alcohol or drug abuse or other conditionals as judged by the investigator.","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Prostate Size Based on Trans Rectal Ultra Sound (TRUS) at Week 12 (Full Analysis Set)","description":"TRUS is a method of measuring the size of the prostate.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-36.0","spread":"14.5"},{"groupId":"OG001","value":"-35.3","spread":"16.7"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Prostate Size Based on Trans Rectal Ultra Sound (TRUS) at Week 12 (Per Protocol Analysis Set)","description":"TRUS is a method of measuring the size of the prostate.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-36.2","spread":"14.5"},{"groupId":"OG001","value":"-35.4","spread":"16.9"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total International Prostate Symptom Score (IPSS) at Week 4, 8, and 12","description":"The IPSS is a tool commonly used to assess the severity of lower urinary tract symptoms (LUTS), and to monitor the progress of the disease once treatment has been initiated. The participant completes a questionnaire containing 7 questions regarding incomplete emptying, frequency, intermittency, urgency, weak stream, straining, and nocturia. Each question is assigned a score of 0-5. The total score is then classified according to the following scale: 0 to 7 = mildly symptomatic; 8 to 19 = moderately symptomatic; and 20 to 35 = severely symptomatic.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.21","spread":"5.05"},{"groupId":"OG001","value":"0.36","spread":"4.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.53","spread":"5.43"},{"groupId":"OG001","value":"0.02","spread":"5.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.71","spread":"5.54"},{"groupId":"OG001","value":"0.11","spread":"5.13"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Serum Testosterone Levels During the Study","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.8","spread":null},{"groupId":"OG001","value":"-4.22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.77","spread":null},{"groupId":"OG001","value":"-4.26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.81","spread":null},{"groupId":"OG001","value":"-4.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Serum Prostate-Specific Antigen (PSA) Levels During the Study","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.3","spread":null},{"groupId":"OG001","value":"-5.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.95","spread":null},{"groupId":"OG001","value":"-8.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.35","spread":null},{"groupId":"OG001","value":"-9.05","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Serum Oestradiol Levels During the Study","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.55","spread":null},{"groupId":"OG001","value":"-1.65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":null},{"groupId":"OG001","value":"-1.65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.55","spread":null},{"groupId":"OG001","value":"-1.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Quality of Life (QoL) Related to Urinary Symptoms at Each Visit","description":"The IPSS questionnaire included an additional single question to assess the participant's QoL in relation to his urinary symptoms. The question was: 'If you were to spend the rest of your life with your urinary condition the way it is now, how would you feel about that?' The possible answers to this question ranged from 'delighted' (a score of '0') to 'terrible' (a score of '6').","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.07","spread":"1.31"},{"groupId":"OG001","value":"0.16","spread":"0.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.24","spread":"1.34"},{"groupId":"OG001","value":"0.05","spread":"1.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.33","spread":"1.46"},{"groupId":"OG001","value":"0.16","spread":"1.4"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Markedly Abnormal Values in Vital Signs and Body Weight","description":"This outcome measure included incidence of markedly abnormal changes in blood pressure (systolic and diastolic), pulse, and body weight. The table presents the number of participants with normal baseline and at least one post-baseline markedly abnormal value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Markedly Abnormal Values in Safety Laboratory Variables","description":"The figures present the number of participants who had abnormal (defined as above upper limit of normal range (ULN)) levels of safety laboratory variables. Only the laboratory variables that had at least one percentage of participants in either group with abnormal value are presented, more variables were included in the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":181},"commonTop":["Hot flush","Injection site pain","Injection site erythema","Erectile dysfunction","Asthenia"]}}}